Glioblastoma Platelet Activation Study

Completed

• Conditions: Glioblastoma; Circulating Platelet-monocyte Conjugates

• Registration Number: NCT02887417
• Lead Sponsor: University Medicine Greifswald

Brief Summary

Glioblastoma face an increased risk of venous or arterial thromboembolism. Furthermore, the most frequent immune cells in glioblastoma are tumor associated macrophages, which find theirself in an anti-inflammatory (M2) phenotype.

Increased conjugates between circulating platelets and monocytes reflect an pro-inflammatory status.

Detailed Description

Glioblastoma face an increased risk of venous or arterial thromboembolism. Furthermore, the most frequent immune cells in glioblastoma are tumor associated macrophages, which find theirself in an anti-inflammatory (M2) phenotype.

Increased conjugates between circulating platelets and monocytes reflect an pro-inflammatory status.

Study Timeline

• Study Start: 2016-01
• Study First Submitted: 2016-08-18
• Study First Submitted QC: 2016-08-29
• Study First Posted: 2016-09-02
• Primary Completion: 2016-10
• Study Completion: 2016-12
• Status Verified: 2017-07
• Last Update Submitted: 2017-07-31
• Last Update Posted: 2017-08-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 21

Inclusion Criteria

• MR-morphological suspicion for glioblastoma
• informed consent

Exclusion Criteria

• no informed consent

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Mean P-selectine expression in all platelets	01/ 2016 - 10/ 2016
Mean CD63 expression in all platelets	01/ 2016 - 10/ 2016
Mean CD40 Expression in all platelets	01/ 2016 - 10/ 2016
Mean platelet-monocyte-conjugate formation in the monocyte population	01/ 2016 - 10/ 2016

Trial Locations

Locations (1)

Department of Neurosurgery; 🇩🇪 Greifswald, Germany